• About Us
  • Contact us
  • Editorial Policy
  • Terms & Conditions
  • Privacy Policy
Saturday, June 10, 2023
SUBSCRIBE
London Daily Post
  • Home
  • UK
  • World
  • Business
  • Politics
  • Finance
  • Tech
  • Entertainment
  • Lifestyle
  • Sports
No Result
View All Result
  • Home
  • UK
  • World
  • Business
  • Politics
  • Finance
  • Tech
  • Entertainment
  • Lifestyle
  • Sports
No Result
View All Result
London Daily Post
No Result
View All Result
ADVERTISEMENT

US launches trial for blood tests that promise to catch cancers earlier

Editorial Board by Editorial Board
September 13, 2022
in Tech News
Reading Time: 2 mins read
0


Questions remain about how to interpret MCED test results. Only certain blood tests can identify in which organ the cancer is actually located. Laboratory tests must be done on potentially cancerous tissue to confirm a diagnosis, but a person’s entire body cannot be biopsied. False positives remain a problem for the entire field of cancer detection, which by design involves sifting through reams of healthy evidence to find cancer. Galleri, the MCED furthest down the road to widespread use, incorrectly flagged 57 healthy blood samples as cancerous in the aforementioned study.

There’s also the risk of jumping the gun: Some cancers never become invasive or life-threatening, but early detection could lead to harsh treatment like chemotherapy. Some data suggest that less worrisome cancers actually show up less often in the bloodstream, which could minimize this problem.

The NIC assay will help determine how blood test results for cancer should be interpreted and should provide a standard approach for launching cancer screening studies as companies flood the field with new tests.

“I don’t think most companies tend to want to compare their tests head-to-head,” says Timothy Rebbeck, a professor of cancer prevention at Harvard. “It is expensive and difficult. So someone else, a neutral party like the NCI, needs it.”

Rebbeck believes that the blood tests that the new trial will verify will be most useful in cases of pancreatic, liver and ovarian cancers, which often kill and have no other form of screening. Still, longer trials are needed to confirm whether the time bought by these blood tests saves lives.

But Rebbeck is optimistic about the Cancer Moonshot’s ultimate goal: “It seems very realistic to me to think that we could cut death in half,” she says.



Source link

Share this:

  • Twitter
  • Facebook

Related Posts

Tech News

The Download: a promising new fuel, and why our phones struggle with wildfires

June 9, 2023

New York-based startup Amogy believes the key to solving this problem lies in harnessing ammonia, one of the world's most...

Tech News

Apple’s headset challenges, and what AI can learn from nuclear safety

June 6, 2023

The "one more thing" announced by Apple at its Worldwide Developers Conference (WWDC) this year was the industry's worst-kept secret....

Tech News

AI films, and the threat of microplastics

June 2, 2023

The Frost nails its strange and disconcerting atmosphere in its opening shots. Huge frozen mountains, a makeshift camp of military-style...

Tech News

Meet the longevity obsessives, and how China’s regulating AI

May 31, 2023

—Jessica Hamzelou Earlier this month, I traveled to Montenegro for a meeting of longevity enthusiasts, people interested in extending human...

Next Post

Summary of Briefing on Honda Motorcycle Business

POPULAR

Entertainment

Elliot Page Recalls ‘Inception’ Cast ‘Full Of Cis Men’ Making Him So Anxious He Got Shingles

June 9, 2023
Finance News

A new bull market in stocks? Thank the VIX, says Fundstrat’s Tom Lee

June 9, 2023
World News

Ukraine presses counteroffensive as flood evacuations continue in south

June 9, 2023
  • About Us
  • Contact us
  • Editorial Policy
  • Terms & Conditions
  • Privacy Policy

© 2022 London Daily Post. All Rights Reserved.

No Result
View All Result
  • Home
  • UK
  • World
  • Business
  • Politics
  • Finance
  • Tech
  • Entertainment
  • Lifestyle
  • Sports